What Is H. pylori and Why Does It Matter?
Helicobacter pylori is a gram-negative, spiral-shaped bacterium that colonizes the stomach lining (gastric mucosa) of roughly 44% of the world's population — approximately 3.5 billion people. The infection is far more prevalent in developing countries, where 70–90% of adults may be infected, compared to 20–40% in high-income nations. Transmission is primarily fecal-oral or oral-oral, making childhood crowding and sanitation the dominant risk factors.
For most of the 20th century, stomach ulcers were blamed on stress, spicy food, and acid overproduction. That changed in 1984, when Australian physicians Barry Marshall and J. Robin Warren demonstrated that H. pylori caused gastritis and peptic ulcer disease — a discovery so contested that Marshall famously drank a Petri dish of the bacteria to prove it. They received the Nobel Prize in Physiology or Medicine in 2005. The implications were enormous: a condition affecting hundreds of millions was caused by an infection, not lifestyle choices.
How H. pylori Survives in Acid
The stomach is one of the most hostile environments in the human body — pH 1.5 to 3.5, designed to kill microorganisms. H. pylori has evolved several mechanisms to not only survive but thrive there:
- Urease enzyme: H. pylori produces urease in large quantities, which converts urea (present in gastric secretions) into ammonia and carbon dioxide. The ammonia neutralizes surrounding acid, creating a microenvironment with tolerable pH around the bacterium.
- Spiral morphology + flagella: Its corkscrew shape and multiple polar flagella allow it to burrow into the protective mucous layer lining the stomach wall, where acid concentration is lower.
- Adhesins: Surface proteins (BabA, SabA) anchor the bacterium to gastric epithelial cells, preventing it from being washed away by peristalsis.
- Disruption of the mucous layer: Over time, H. pylori degrades the mucous barrier, exposing underlying epithelial cells to gastric acid — the primary driver of ulcer formation.
- Immune evasion: The bacterium modifies its lipopolysaccharide to reduce immune recognition and can suppress T-cell responses, enabling decades-long chronic infection.
Symptoms: Why Most People Don't Know They Have It
The vast majority of H. pylori infections — 75 to 80% — are asymptomatic. The immune system contains the infection without eliminating it, and the bacterium causes low-grade inflammation that doesn't produce noticeable symptoms. When symptoms do occur, they typically reflect gastritis or peptic ulcer disease:
- Epigastric pain — a burning or gnawing sensation in the upper abdomen, often between meals or at night
- Bloating and early satiety — feeling full quickly after eating, often with gas
- Nausea — particularly in the morning or after meals
- Iron deficiency anemia — H. pylori consumes iron and reduces its absorption; this is a well-established but underrecognized association, particularly in premenopausal women
- Unexplained weight loss — in more advanced disease
A critical point: symptoms are a poor proxy for infection. Many people with active H. pylori infection have no GI complaints, while those with prominent symptoms may have functional dyspepsia without H. pylori. Testing — not symptom patterns — determines infection status.
The Ulcer Connection: Rewriting Medical History
H. pylori is responsible for approximately 90% of duodenal ulcers and 70–80% of gastric ulcers. It achieves this through two mechanisms: direct damage to the mucous barrier (exposing the epithelium to acid) and stimulation of gastrin secretion, which increases acid output. NSAIDs (aspirin, ibuprofen, naproxen) account for most of the remaining ulcer cases by inhibiting prostaglandin synthesis, which normally maintains the mucosal barrier.
Before the H. pylori discovery, standard ulcer treatment was antacids and dietary modification — effective at relieving symptoms but useless at addressing the cause. Recurrence rates were near 70–80% within one year. After bacterial eradication, ulcer recurrence rates drop below 5%. This single insight transformed gastroenterology.
The Cancer Link: H. pylori as a Group 1 Carcinogen
The International Agency for Research on Cancer (IARC) classified H. pylori as a Group 1 carcinogen — the highest classification, meaning definite causation in humans — in 1994. Infected individuals have approximately a 6-fold higher risk of developing non-cardia gastric adenocarcinoma compared to uninfected individuals. Gastric cancer is the 5th most common cancer globally and the 4th leading cause of cancer death, killing approximately 769,000 people per year (GLOBOCAN 2020).
The carcinogenic pathway follows a predictable cascade described by Correa: H. pylori → chronic active gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma. This progression typically takes decades. H. pylori virulence factors, particularly the cytotoxin-associated gene A (CagA) protein, drive more aggressive mucosal damage and higher cancer risk. Eradicating H. pylori before intestinal metaplasia develops reduces gastric cancer risk significantly; eradication after metaplasia provides partial but meaningful benefit.
H. pylori is also strongly associated with gastric MALT lymphoma (mucosa-associated lymphoid tissue lymphoma), and eradication alone achieves remission in 60–80% of low-grade MALT lymphoma cases — one of the few examples of cancer treated by antibiotics.
Diagnosis: Which Test to Use and When
Non-Invasive Tests
Urea Breath Test (UBT) — the gold standard for non-invasive diagnosis and for confirming eradication after treatment. The patient swallows labeled urea (C-13 or C-14); if H. pylori is present, its urease converts the urea to labeled CO₂, which is detected in exhaled breath. Sensitivity and specificity exceed 95%. PPIs and antibiotics must be stopped 2–4 weeks before testing to avoid false negatives.
Stool Antigen Test (SAT) — detects H. pylori proteins in stool using monoclonal antibodies. Sensitivity and specificity are approximately 94% and 97%, respectively, with the monoclonal antibody versions. Comparable to UBT for confirming eradication and useful in settings where UBT is unavailable. Also requires PPI cessation 2 weeks prior.
Serology (IgG antibody testing) — largely discouraged in current guidelines. Antibodies persist for months to years after eradication, making it impossible to distinguish active from past infection. Useful only in specific epidemiological contexts.
Invasive Tests (Endoscopy-Based)
Rapid Urease Test (RUT) — a biopsy specimen is placed in a urea-containing medium; color change indicates urease activity (H. pylori). Fast, inexpensive, and highly specific. Done during upper endoscopy.
Histology — biopsy specimens stained with Giemsa or Warthin-Starry stain allow direct visualization of the bacterium and assessment of gastric mucosal damage (gastritis grade, atrophy, metaplasia). Most accurate for overall mucosal assessment; recommended when malignancy is a concern.
Culture with sensitivity testing — allows antibiotic susceptibility profiling, critical in regions with high clarithromycin resistance. Recommended by Maastricht V guidelines before first-line therapy in areas where clarithromycin resistance exceeds 15%.
Current guidelines (Maastricht V/Florence, ACG 2017) recommend testing anyone with active peptic ulcer disease, gastric MALT lymphoma, after resection for early gastric cancer, first-degree relatives of gastric cancer patients, and those with unexplained iron deficiency anemia. A "test-and-treat" strategy (non-invasive testing followed by eradication if positive) is appropriate for uninvestigated dyspepsia in populations with H. pylori prevalence above 10%.
Diagnostic Tests: Comparative Evidence
| Test | Sensitivity | Specificity | Best Use |
|---|---|---|---|
| Urea Breath Test | 95–98% | 95–98% | First-line non-invasive; confirm eradication |
| Stool Antigen Test | 92–96% | 95–97% | Alternative to UBT; post-treatment confirmation |
| Histology (endoscopy) | 93–99% | 95–99% | When mucosal assessment / malignancy concern |
| Serology (IgG) | 85–95% | 79–90% | Not recommended for active infection or eradication check |
Treatment: The Eradication Protocols
The goal of treatment is complete eradication — confirmed by UBT or stool antigen test at least 4 weeks after completing antibiotics and 2 weeks after stopping PPIs. Incomplete eradication is worse than no treatment in some respects, as it can select for antibiotic-resistant strains.
Standard Triple Therapy (Declining Efficacy)
The traditional first-line regimen — PPI twice daily + amoxicillin 1g twice daily + clarithromycin 500mg twice daily for 14 days — once achieved eradication rates above 85%. Rising clarithromycin resistance has reduced efficacy to 70–85% or lower in many regions. A 14-day course outperforms 7-day regimens and should be standard when triple therapy is used. Triple therapy remains appropriate in regions where clarithromycin resistance rates are below 15% and when susceptibility testing confirms sensitivity.
Bismuth Quadruple Therapy (2026 Preferred)
Due to clarithromycin resistance rates of 20–40% in parts of Europe, Asia, and North America, bismuth-based quadruple therapy is now recommended as first-line in most high-resistance regions by the 2017 Maastricht V guidelines. The regimen: PPI twice daily + bismuth subsalicylate (or subcitrate) four times daily + metronidazole 500mg three times daily + tetracycline 500mg four times daily, for 10–14 days. Eradication rates consistently exceed 90%, largely because resistance to tetracycline and bismuth is rare.
Concomitant Therapy and Levofloxacin Regimens
Concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole simultaneously, 14 days) achieves ~88–90% eradication and does not require culture-based susceptibility testing. Levofloxacin-based triple therapy (PPI + amoxicillin + levofloxacin) is a second-line option but is limited by rising fluoroquinolone resistance. Rifabutin-based regimens are reserved for third-line rescue therapy.
The Antibiotic Resistance Problem
Clarithromycin resistance is the single biggest threat to H. pylori eradication efficacy. Point mutations in the 23S rRNA gene confer high-level resistance, reducing clarithromycin-containing regimen efficacy from ~85% to ~30–40% in resistant strains. Resistance rates vary dramatically by geography: approximately 5–10% in some Northern European countries, rising to 30–40% in Southern Europe, China, and Turkey. Before prescribing triple therapy containing clarithromycin, local resistance data or ideally patient-level culture and sensitivity testing should inform the decision.
Metronidazole resistance is also common (30–50% in many regions) but is partially overcome by higher doses, longer duration, and combination with other agents, making bismuth quadruple therapy resilient despite metronidazole resistance.
Post-Eradication Gut Restoration
H. pylori eradication regimens — particularly bismuth quadruple therapy — deliver a substantial antibiotic hit to the gut microbiome. Studies using 16S rRNA sequencing show significant reductions in Lactobacillus, Bifidobacterium, and overall alpha diversity immediately post-treatment, with most markers recovering by 4–8 weeks but some changes persisting for months. Deliberate microbiome support during and after treatment is justified by evidence.
Probiotics During and After Eradication
Saccharomyces boulardii is the most extensively studied probiotic in H. pylori eradication. A 2007 meta-analysis (Szajewska et al.) of randomized controlled trials found that S. boulardii supplementation alongside triple therapy significantly increased eradication rates (OR 2.07) and significantly reduced overall antibiotic-associated side effects, particularly diarrhea (RR 0.45). A dose of 500–750mg twice daily, taken 2 hours apart from antibiotics and continued for 4 weeks post-treatment, is a reasonable evidence-based approach.
Lactobacillus reuteri (particularly the DSM 17938 strain) has demonstrated anti-H. pylori activity in vitro and modestly improved eradication rates in combination therapy trials. Its primary value may be in reducing GI side effects — nausea, diarrhea, bloating — that frequently lead to treatment non-compliance. A combination probiotic containing L. reuteri, L. acidophilus, and Bifidobacterium strains is a reasonable post-treatment protocol for 4–8 weeks.
Natural Adjuncts with Evidence
Sulforaphane from broccoli sprouts has demonstrated inhibitory activity against H. pylori in multiple studies. A 2009 study by Yanaka et al. (published in Cancer Prevention Research) found that consuming 70g of broccoli sprouts daily (providing approximately 35–40mg sulforaphane) for 8 weeks reduced urease activity, stool and breath antigen levels, and gastric mucosal inflammation in H. pylori-positive subjects compared to controls consuming alfalfa sprouts. Sulforaphane disrupts H. pylori's flagella assembly and increases expression of phase 2 detoxification enzymes in the gastric mucosa. While not a replacement for antibiotic therapy, sulforaphane supplementation (as a standardized broccoli sprout extract standardized to sulforaphane/glucoraphanin) may serve as a useful adjunct, particularly in cases of treatment failure or reinfection prevention.
Mastic gum (Pistacia lentiscus resin) has demonstrated in vitro bactericidal activity against H. pylori, and a small RCT (Al-Habbal et al. 1984) showed symptom improvement. However, clinical evidence for actual H. pylori eradication with mastic gum alone remains limited and inconsistent. It may have a role in symptom management and adjunctive use rather than primary eradication.
Lactoferrin (bovine) has shown modest additive effects on eradication rates when combined with standard triple therapy, with meta-analyses suggesting a 15–20% improvement in eradication. Its mechanism involves iron chelation (disrupting H. pylori metabolism) and direct membrane disruption.
Reinfection Rates and Long-Term Outlook
After successful eradication, reinfection rates in developed countries are low — approximately 1–3% per year. In developing countries with ongoing sanitation challenges, reinfection rates can exceed 10% per year. The distinction between true reinfection (acquiring a new strain) and recrudescence (regrowth of incompletely eradicated bacteria) is clinically important; recurrence within 6–12 months of treatment is more likely recrudescence, while recurrence after 12 months is more likely true reinfection. Confirmed eradication with UBT or stool antigen test is therefore essential before attributing a later positive test to reinfection.
For those with a history of gastric ulcer, gastric MALT lymphoma, or early gastric cancer, ongoing surveillance endoscopy is recommended even after successful eradication, as mucosal changes (atrophy, metaplasia) that developed before eradication may persist. The benefit of eradication for cancer risk reduction is greatest when treatment occurs before these pre-malignant changes develop.
References and Further Reading
- Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;323(8390):1311–1315. [Nobel Prize discovery]
- Malfertheiner P, et al. (European Helicobacter and Microbiota Study Group). Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
- Yanaka A, et al. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori–infected mice and humans. Cancer Prevention Research. 2009;2(4):353–360.
- Szajewska H, et al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary Pharmacology & Therapeutics. 2010;32(9):1069–1079.
- IARC Working Group. Schistosomes, Liver Flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 61. IARC Press; 1994.